Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193789 | 1.00 | CTSK (0.55) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL1194009 | 1.00 | CTSK (0.55) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL18989601 | 0.88 | CTSK (0.51) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL18989589 | 0.88 | CTSK (0.51) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL7877056 | 0.85 | MIF (0.47) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL5500503 | 0.85 | CTSK (0.41) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL18989452 | 0.84 | CTSK (0.50) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL18989598 | 0.84 | CTSK (0.50) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL18989457 | 0.84 | CTSK (0.50) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL391359 | 0.84 | TRPA1 (0.47) | CTSKCTSSMAPTCTSLPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| EP-3214086-B1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| EP-3214086-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | Ube Industries, Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-3066065-A1 | CATALYTIC HYDROGENATION FOR PRODUCING AMINES FROM CARBOXYLIC ACID AMIDES, CARBOXYLIC ACID DIAMIDES, DI-, TRI-, OR POLYPEPETIDES, OR PEPTIDE AMIDES | Evonik Degussa GmbH (DE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067450-A1 | CATALYTIC HYDROGENATION FOR PRODUCING AMINES FROM CARBOXYLIC ACID AMIDES, CARBOXYLIC ACID DIAMIDES, DI-, TRI-, OR POLYPEPETIDES, OR PEPTIDE AMIDES | EVONIK INDUSTRIES AG (DE) | 2015-05-14 | — | — | WO | disclosed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | disclosed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
| EP-0356223-A2 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO. INC. (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, KCNJ11 | CTSK 3161/4885CTSS 3551/4885MAPT 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.